Clinical Research Directory

Dose escalation part: Inclusion Criteria: * Histologically or cytologically confirmed unresectable, locally advanced or metastatic solid tumor malignancies * Patients with a malignancy not amenable to surgical intervention * Patients with measurable disease and progression radiologically assessed * Patients with disease progression after treatment with available standard of care therapies that are known to confer clinical benefit or who are intolerant to treatment. * Patients with available archived tumor biopsy specimens or agree to mandatory biopsy * Estimated life expectancy ≥ 12 weeks * Adequate haematological function * Adequate renal function * Adequate hepatic function Exclusion Criteria: * Pregnant and lactating women * Major surgery within 4 weeks prior to the first IMP administration or not recovered from the surgery * Patients with serious/active/uncontrolled infection or infection requiring parenteral antibiotics, within 2 weeks prior to first IMP administration * Active Hepatitis B Virus infection * Carriers of HIV antibodies * Patients with active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to first IMP administration * History of organ transplantation * History of gastrointestinal perforation, or intra-abdominal abscess within 28 days of inclusion * History of cirrhosis * History of pulmonary fibrosis or relevant uncontrolled chronic pulmonary condition * Treatment with systemic immunosuppressive therapy * Active autoimmune disease * Administration of a live vaccine within 28 days prior to inclusion